We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
On March 20, 2012, in Mayo Collaborative Services et al. v. Prometheus Laboratories, Inc., No. 10-1150 (S. Ct. 2012), the Supreme Court held that claims directed to methods of optimizing the dose of specific drugs used in the treatment of specific conditions are invalid under 35 U.S.C. 101 because they impermissibly claim laws of nature
